Resources

Two biomarkers may be associated with cardiovascular events and death in type 2 diabetes patients, researchers reported at EASD.…

Aggressively lowering blood pressure and blood glucose together won’t provide any microvascular benefits to type 2 diabetes patients, researchers said….

Dementia risk may rise when glucose gets out of control, particularly after meals, according to a longitudinal study.…

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin….

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath Mr. WWB was referred to the diabetes educator by a nurse working on a medical ward. “We have a man here on the medical ward with COAD (chronic obstructive airways disease). …

This week we continue with Part 4 of our series of Homerun Slides on Pathophysiology in the Treatment of Type 2 Diabetes: Newer Agents. Slides this week cover Exenatide, a synthetic version of Exendin-4 which is found in the saliva of the Gila monster….

 A National Randomized Trial Lisa M. Schwartz, MD, MS; Steven Woloshin, MD, MS Background Many new drugs are aggressively promoted. The public may not realize that even with US Food and Drug Administration (FDA) approval, important uncertainties about the benefits and harms of these drugs remain. We assessed the US …

Once-A-Year Non-Injectable Byetta The DUROS delivery system aims to reshape the way diabetes is treated by offering patients and their health care providers with a more convenient long term treatment regiment. The result is the investigational treatment now in late stage development — ITCA 650. As part of a robust …

According to the latest figures from the International Diabetes Federation (IDF), released in advance of a UN summit on non-communicable diseases, 366 million people worldwide now have diabetes.…

Intensive glucose-lowering may protect against end-stage renal disease (ESRD) in diabetic patients, according to an analysis of data from the ADVANCE trial….